Related Experiment Videos
Non-phospholipid vesicles for pulmonary glucocorticoid delivery
Claudio Terzano1, Luigi Allegra, Franco Alhaique
1Department of Cardiovascular and Respiratory Sciences, Faculty of Medicine University La Sapienza, Roma, Italy.
Summary
New non-phospholipid vesicles effectively deliver beclomethasone dipropionate through simulated mucus. This innovative formulation enhances drug penetration for asthma and COPD treatments.
Area of Science:
- Pharmaceutical Sciences
- Drug Delivery Systems
- Respiratory Medicine
Background:
- Asthma and COPD treatments require effective delivery of inhaled drugs, particularly corticosteroids, which can be hindered by mucus in the airways.
- Conventional liposomes face challenges, but non-phospholipid vesicles offer advantages in stability, cost, and material availability for drug formulation.
- Improved aerosol formulations are needed to enhance local effects and mucus penetration for better therapeutic outcomes in respiratory diseases.
Purpose of the Study:
- To develop an innovative lung delivery formulation capable of permeating the mucous layer for treating asthma and COPD.
- To entrap beclomethasone dipropionate, a key corticosteroid, into non-phospholipid vesicles for enhanced airway delivery.
- To investigate the potential of these novel vesicles as a superior drug delivery system for respiratory conditions.
Main Methods:
- Beclomethasone dipropionate was entrapped in non-phospholipid vesicles, with the optimal composition selected based on entrapment efficiency.
- Vesicles were characterized using freeze-fracture microscopy and dynamic light scattering after jet nebulization.
- In vitro diffusion experiments utilizing a three-compartment cell apparatus with simulated mucus (0.1% mucin dispersion) evaluated drug permeation.
Main Results:
- Non-phospholipid vesicles were successfully formulated with beclomethasone dipropionate.
- Characterization confirmed the morphology and size of the prepared vesicles.
- In vitro diffusion studies demonstrated the ability of the vesicles to permeate the simulated mucus barrier, indicating enhanced drug delivery potential.
Conclusions:
- Non-phospholipid vesicles represent a promising platform for the pulmonary delivery of beclomethasone dipropionate.
- This novel formulation has the potential to overcome mucus-related drug delivery challenges in asthma and COPD.
- Further research into this drug delivery system could lead to improved inhaled therapies for respiratory diseases.